Abstract-The effect of 450191 -
450191-S, 1 -(2-o-chlorobenzoyl-4 chlorophenyl)-5-glycylaminomethyl-3 dimethylcarbamoyl-1 H-1,2,4-triazole hydro chloride dehydrate, is one of the 1 H-1 ,2,4 triazolyl benzophenone derivatives newly synthesized by Hirai et al. (1 ) . This compound has been reported to possess sedative, anti convulsive, anti-anxiety and sleep-inducing actions with a weak muscle relaxation property (2-5). It has been also reported that orally administered 450191-S is converted to benzodiazepine (BZP) derivatives (M-1, M-2, M-A, M-3 and M-4) in the alimentary canal by the action of aminopeptidase (2-5). These results suggest that the orally administered 450191 -S may exhibit BZP-like actions after converting to these metabolites.
Recent studies on the BZP receptor in the central nervous system have revealed that this receptor is coupled with ; -aminobutyric acid (GABA) receptor as well as chloride ionophore in synaptic membranes, and the BZP receptor binding is activated specifically by . Our recent studies also have indicated that 4501 91 -S and its active metabolites selectively activate synaptic GABA receptor binding with a low affinity, and the potency of these activations is well-correlated with the central actions of this drug determined in vivo (in preparation). These facts suggest that in vivo adminis tration of 450191 -S as well as other BZPs may affect the cerebral content of GABA. In the present study, we have attempted, therefore, to examine the effect of in vivo administration of 450191-S on the cerebral contents of various amino acids including GABA in comparison with that of nitrazepam.
Male Shionogi-SD mice weighing 28-40 g were used. The 450191-S and nitrazepam, kindly provided by Shionogi and Co., Ltd. (Osaka, Japan), were suspended in 1 % Gum Arabic and administered orally to mice. Control animals received an equal amount of the vehicle only. Six hours after the adminis tration, these mice were killed with focused microwave irradiation (4.5 kW, 0.8 sec) on the head. Each brain was removed and chilled on ice. The brain was homogenized in 5 vol. of ice-cold 10% trichloroacetic acid, and the homogenate was centrifuged at 8,000 g for 30 min at 4°C. The supernatant thus obtained was used for the assay of various amino acids. For the measurement of amino acids, an HPLC system consisting of a Model LC 3A from Shimadzu Seisakusho, Ltd. (Kyoto, Japan) was used. The liquid chromatography system employed was essentially the same as previously reported by Ida and Kuriyama (10). Briefly, the column (15 cmx4 mm i.d.) packed with cation-exchange resin, ISC-07/ S1504, was used at 55'C. Three types of eluents were used with a flow rate of 0.5 ml/ min: 0.067 N sodium citrate (pH 3.25 and 4.25), 0.2 N sodium citrate (pH 9.00). The time program of the stepwise gradient elution system (pH 3.25, 4.25 and 9.00) employed was 15, 30 and 35 min, respectively. Amino acids were detected using o-phthalaldehyde, and fluorescence of each eluent was measured spectrofluorometrically at excitation and emis sion wavelengths of 348 and 450 nm, respectively. The peak for each amino acid was identified by comparison with the retention time obtained from each authentic compound.
The compounds used in the assay were quantified by the measurement of each peak area using an on-line computing integrator. The oral administration of an equi-amount of nitrazepam also exhibited a statistically significant decrease in the contents of glycine and alanine, but induced the increase of aspartic acid in the brain. The latter effect was in sharp contrast with that of 450191-S, which exhibited the decrease of aspartic acid in the brain. Since aspartic acid is known as a potential candidate for exitatory neurotransmitter in the mammalian central nervous system (CNS) and the spinal cord has interneurons activated by this amino acid (111), it seems possible that this differential effect on aspartic acid may be related to a weaker muscle relaxation property of 4501 91 -S than that of nitrazepam (2-5). at 15 min prior to the sacrifice of 4501 91 -S-treated animals induced a rapid reversal of the decreased levels of aspartic acid acid glycine in the brain (Fig. 1 ) 
